Vistusertib
Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
Product Specifications
CAS Number
[1009298-59-2]
Product Name Alternative
AZD2014
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; mTOR
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AZD2014.html
Purity
99.6900
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(NC)C1=CC=CC(C2=CC=C3C(N=C(N4[C@@H](C)COCC4)N=C3N5[C@@H](C)COCC5)=N2)=C1
Molecular Formula
C25H30N6O3
Molecular Weight
462.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Guichard SM, et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol Cancer Ther. 2015 Nov;14 (11) :2508-18.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
MTOR; mTORC1; mTORC2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15312914 1 Vial
Lentiviral human LPIN3 shRNA (UAS) - Lentiviral human LPIN3 shRNA (UAS, RFP) (25)
Ask
View Details 
